AstraZeneca antibody drug important as preventative COVID-19 therapy – exec

Published by

(Reuters) – An AstraZeneca senior executive said on Monday the drugmaker’s COVID-19 antibody cocktail would have a “real advantage” in preventing the coronavirus infection compared with use as a treatment, after trials showed promise in both settings. “I don’t think treatment is where we are going to be competing,” Mene Pangalos, executive vice president for bio-pharmaceuticals R&D at AstraZeneca, said during a media briefing. “It’s good that we know this can work in the treatment setting. If and when this is approved it will be used in the treatment setting as well. But the real differentiato…

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *